Suda’s lead product ZolpiMist is the oro-mucosal spray version of the blockbuster insomnia drug Ambien,...
16.04 Wed 08 Jul 2020
CardieX looks to expand into clinical and consumer markets
Medlab Clinical inks UK and US distribution deals for nutraceuticals
Opyl to use artificial intelligence to digitally transform Australia’s healthcare sector
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.